{"id":"3e1e3087-37e2-5fa1-9a93-7b25187e0034","stable_key":"bf161ddf-8b82-5d65-b86d-0b41245aac61:phlorizin-sglt2-structure","predicate":"stabilizes_inward_conformation_of","statement":"Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"f46ed188-9635-5fbb-8f27-9394ea34d6da","mechanism_event_label":"Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.","subject":{"id":"3516a0ba-1f72-5e1b-bccb-7fca992f96f7","slug":"phlorizin","display_name":"Phlorizin","entity_type_key":"small_molecule"},"object":{"id":"67c23d71-d6f4-59a4-bdf3-164b8080a39d","slug":"human-sglt2-map17-complex","display_name":"Human SGLT2-MAP17 transporter complex","entity_type_key":"protein_complex"},"evidence_count":1,"mechanism_event":{"id":"f46ed188-9635-5fbb-8f27-9394ea34d6da","stable_key":"bf161ddf-8b82-5d65-b86d-0b41245aac61:phlorizin-sglt2-structure-event","event_type":"observed_relationship","label":"Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.","description":"Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"3516a0ba-1f72-5e1b-bccb-7fca992f96f7","slug":"phlorizin","display_name":"Phlorizin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"67c23d71-d6f4-59a4-bdf3-164b8080a39d","slug":"human-sglt2-map17-complex","display_name":"Human SGLT2-MAP17 transporter complex","entity_type_key":"protein_complex"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"38de8704-84db-5770-ac1d-242cd787e798","slug":"sodium-ion","display_name":"Sodium ion","entity_type_key":"ion"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Phlorizin and comparator synthetic inhibitors","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Acute","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Purified human SGLT2-MAP17 complex","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A bound structure explains inhibition but does not establish human pharmacokinetics; synthetic inhibitors used different outward-facing poses.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Phlorizin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"phlorizin","display_name":"Phlorizin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Purified human SGLT2-MAP17 complex","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Cryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. (2024). https://pubmed.ncbi.nlm.nih.gov/38057552/ DOI: 10.1038/s41594-023-01134-0","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Cell-free structural and transport analysis","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Cryo-EM structures and inhibitor kinetics","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"18b4c909-dad1-57e3-929b-feb9849e3b5c","evidence_kind":"source_excerpt","locator":"Lines 33-42","start_line":33,"end_line":42,"excerpt":"## phlorizin-sglt2-structure\nCryo-EM placed phlorizin in an inward-facing human SGLT2-MAP17 complex, and biphasic kinetics suggested access from extracellular and intracellular sides.\nModel/species: Purified human SGLT2-MAP17 complex\nTissue/system: Cryo-EM structures and inhibitor kinetics\nExposure: Phlorizin and comparator synthetic inhibitors\nRoute: Cell-free structural and transport analysis\nDuration: Acute\nLimits: A bound structure explains inhibition but does not establish human pharmacokinetics; synthetic inhibitors used different outward-facing poses.\nPrimary reference: Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. (2024). https://pubmed.ncbi.nlm.nih.gov/38057552/ DOI: 10.1038/s41594-023-01134-0\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Purified human SGLT2-MAP17 complex","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"7d4bfcb9-1665-5686-8b8a-1ad17ad6a4d2","stable_key":"import-bf161ddf-8b82-5d65-b86d-0b41245aac61","title":"Phlorizin: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"13aa8f888801708147608784e74ad34d625b10fd76ea5afd542a3f9328bd40e2","revision_id":"6997ff77-8628-59b7-878c-95fed9d6a622","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}